Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy

• Published in: Journal of virology Vol. 93; no. 13
• Main Authors: Christensen-Quick, Aaron, Massanella, Marta, Frick, Andrew, Rawlings, Stephen A, Spina, Celsa, Vargas-Meneses, Milenka, Schrier, Rachel, Nakazawa, Masato, Anderson, Christy, Gianella, Sara
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.07.2019
• Subjects: Adult; Anti-HIV Agents - therapeutic use; Anti-Retroviral Agents - therapeutic use; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - metabolism; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Coinfection; Cytomegalovirus - genetics; DNA Viruses - metabolism; Herpesvirus 4, Human; HIV Infections - complications; HIV Infections - drug therapy; HIV-1; Humans; Lymphocyte Activation; Male; Programmed Cell Death 1 Receptor; Sexual and Gender Minorities; Virus Replication; Virus Shedding; Virus-Cell Interactions; immune dysfunction; HIV; T cells; CMV
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/JVI.00179-19

Most people living with HIV (PLWH) are coinfected with cytomegalovirus (CMV). Subclinical CMV replication is associated with immune dysfunction and with increased HIV DNA in antiretroviral therapy (ART)-naive and -suppressed PLWH. To identify immunological mechanisms by which CMV could favor HIV persistence, we analyzed 181 peripheral blood mononuclear cell (PBMC) samples from 64 PLWH starting ART during early HIV infection with subsequent virologic suppression up to 58 months. In each sample, we measured levels of CMV and Epstein-Barr virus (EBV) DNA by droplet digital PCR (ddPCR). We also measured expression of immunological markers for activation (HLA-DR CD38 ), cycling (Ki-67 ), degranulation (CD107a ), and the immune checkpoint protein PD-1 on CD4 and CD8 T cell memory subsets. Significant differences in percentages of lymphocyte markers by CMV/EBV shedding were identified using generalized linear mixed-effects models. Overall, CMV DNA was detected at 60/181 time points. At the time of ART initiation, the presence of detectable CMV DNA was associated with increased CD4 T cell activation and CD107a expression and with increased CD8 T cellular cycling and reduced CD107a expression on CD8 T cells. While some effects disappeared during ART, greater CD4 T cell activation and reduced CD107a expression on CD8 T cells persisted when CMV was present (  < 0.01). In contrast, EBV was not associated with any immunological differences. Among the covariates, peak HIV RNA and CD4/CD8 ratio had the most significant effect on the immune system. In conclusion, our study identified immune differences in PLWH with detectable CMV starting early ART, which may represent an additional hurdle for HIV cure efforts. Chronic viral infections such as with HIV and CMV last a lifetime and can continually antagonize the immune system. Both viruses are associated with higher expression of inflammation markers, and recent evidence suggests that CMV may complicate efforts to deplete HIV reservoirs. Our group and others have shown that CMV shedding is associated with a larger HIV reservoir. Subclinical CMV replication could favor HIV persistence via bystander effects on our immune system. In this study, we collected longitudinal PBMC samples from people starting ART and measured immune changes associated with detectable CMV. We found that when CMV was detectable, CD4 T cell activation was higher and CD8 T cell degranulation was lower. Both results may contribute to the slower decay of the size of the reservoir during CMV replication, since activated CD4 T cells are more vulnerable to HIV infection, while the loss of CD8 T cell degranulation may impede the proper killing of infected cells.